To access this material please log in or register

Register Authorize

Interrelationship of arterial calcinosis and osteoporosis. The effect of bisphosphonate therapy on the vascular wall

Aslanyan N. S., Blankova Z. N., Vitsenya M. V., Mikhaylov G. V., Kulev B. D., Ageev F. T.
Federal State Budgetary Institution, “Russian Cardiology Science and Production Center” of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552

Keywords: arterial calcinosis, osteoporosis, treatment

DOI: 10.18087/rhj.2016.3.2215

Arterial calcinosis is an independent RF for cardiovascular events and death. In addition, vascular calcification is associated with increased risk of impaired bone mineral density and fractures. The interrelationship of arterial calcinosis and osteoporosis is based on their common etiology and pathogenesis. Bisphosphonates, the most effective drugs for treatment of osteoporosis, have been shown to reduce arterial calcinosis.
  1. Hoff JA, Chomka EV, Krainik AJ, Daviglus M, Rich S, Kondos GT. Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults. Am J Cardiol. 2001 Jun 15;87 (12):1335–9.
  2. Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven JM, de Leeuw PW, Kroon AA. Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag. 2009;5 (1):185–97.
  3. Bastos Goncalves F, Voute MT, Hoeks SE, Chonchol MB, Boersma EE, Stolker RJ, Verhagen HJ. Calcification of the abdominal aorta as an independent predictor of cardiovascular events: a meta-analysis. Heart. 2012 Jul;98 (13):988–94.
  4. Acierno LJ. Atherosclerosis (arteriosclerosis). The history of cardio­logy. – NY.: Parthenon Publishing Group Inc, 1994. – P.109–26.
  5. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340 (2):115–126.
  6. Virchow R. Cellular pathology as based upon physiological and pathological histology. – NY.: Dover, 1971. – 554p.
  7. Bunting CH. The formation of true bone with cellular (red) marrow in a sclerotic aorta. J Exp Med. 1906 May 25;8 (3):365–76.
  8. Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima versus media. Herz. 2001 Jun;26 (4):245–51.
  9. Danilevicius CF, Lopes JB, Pereira RM. Bone metabolism and vascular calcification. Braz J Med Biol Res. 2007 Apr;40 (4):435–42.
  10. Edmonds ME. Medial arterial calcification and diabetes mellitus. Z Kardiol. 2000;89 (Suppl 2):101–4.
  11. Moe SM, O’Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002 Feb;61 (2):638–47.
  12. Kingma JG Jr, Roy PE. Ultrastructural study of hypervitaminosis D induced arterial calcification in Wistar rats. Artery. 1988;16 (1):51–61.
  13. Doherty TM, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev. 2004 Aug;25 (4):629–72.
  14. Fitzpatrick LA, Turner RT, Ritman ER. Endochondral bone formation in the heart: a possible mechanism of coronary calcification. Endocrinology. 2003 Jun;144 (6):2214–9.
  15. Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ. Coronary artery calcification and aortic pulse wave velo­city in chronic kidney disease patients. Kidney Int. 2004 May;65 (5):1790–4.
  16. Hyder JA, Allison MA, Wong N, Papa A, Lang TF, Sirlin C et al. Association of coronary artery and aortic calcium with lumbar bone density: the MESA abdominal aortic calcium study. Am J Epidemiol. 2009 Jan 15;169 (2):186–94.
  17. Crepaldi G, Maggi S. Epidemiologic link between osteoporosis and cardiovascular disease. J Endocrinol Invest. 2009;32 (4 Suppl): 2–5.
  18. Den Uyl D, Nurmohamed MT, Van Tuyl LH et al. Subclinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther. 2011 Jan 17;13 (1):5.
  19. Dobnig H, Hofbauer L. Osteoporosis and atherosclerosis: common pathway. J Klin Endocrinol Stoffw. 2009;2 (Suppl 3):12–6.
  20. Elmariah S, Delaney JA, O'Brien KD, Budoff MJ, Vogel-Claussen J, Fuster V et al. Bisphosphonate use and prevalence of valvular and vascular calcification in women MESA (the multi-ethnic study of atherosclerosis). J Am Coll Cardiol. 2010 Nov 16;56 (21):1752–9.
  21. Kado DM, Browner WS, Blackwell T, Gore R, Cummings SR. Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res. 2000 Oct;15 (10):1974–80.
  22. Browner WS, Seeley DG, Vogt TM, Cummings SR. Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet. 1991 Aug 10;338 (8763):355–8.
  23. Jorgensen L, Engstad T, Jacobsen BK. Bone mineral density in acute stroke patients: low bone mineral density may predict first stroke in women. Stroke. 2001 Jan;32 (1):47–51.
  24. Mussolino ME, Gillum RF, Madans JH. Bone mineral density and stroke risk. Stroke. 2001 Dec 1;32 (12):2956–7.
  25. Улумбеков Э. Г. Гистология. – М.: «ГЭОТАР-Медиа», 2001. – 694с [Ulumbekov E`.G. Gistologiya. – M.: «GE`OTAR-Media», 2001. – 694s].
  26. Golub EE. Biomineralization and matrix vesicles in biology and pathology. Semin Immunopathol. 2011 Sep;33 (5):409–17.
  27. Persy V, D’Haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol Med. 2009 Sep;15 (9):405–16.
  28. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993 Apr;91 (4):1800–9.
  29. Schor AM, Allen TD, Canfield AE, Sloan P, Schor SL. Pericytes derived from the retinal microvasculature undergo calcification in vitro. J Cell Sci. 1990 Nov;97 (Pt 3):449–61.
  30. Габбасов З. А., Агапов А. А., Сабурова О. С., Руденко Б. А., Балахонова Т. В., Ильина Л. Н. и др. Циркулирующие стромальные остеоноктин-положительные клетки-предшественники и стенозирующий атеросклероз коронарных артерий. Кардиологи­че­ский вестник. 2006;1 (1):10–3 [Gabbasov Z. A., Agapov A. A., Saburova O. S., Rudenko B. A., Balaxonova T. V., Il`ina L. N. i dr. Czirkuliruyushhie stromal`ny`e osteonoktin-polozhitel`ny`e kletki-predshestvenniki i stenoziruyushhij ateroskleroz koronarny`x arterij. Kardiologicheskij vestnik. 2006;1 (1):10–3].
  31. Osako MK, Nakagami H, Koibuchi N, Shimizu H, Nakagami F, Koriyama H et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res. 2010 Aug 20;107 (4):466–75.
  32. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest. 1994 Jun;93 (6):2393–402.
  33. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998 May 1;12 (9):1260–8.
  34. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997 Nov 6;390 (6655):45–51.
  35. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004 Jul;24 (7):1161–70.
  36. Wright HL, McCarthy HS, Mid­dleton J, Marshall MJ. RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med. 2009 Mar;2 (1):56–64.
  37. Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010 Aug 13;285 (33):25103–8.
  38. Hjortnaes J, Butcher J, Figueiredo JL, Riccio M, Kohler RH, Kozloff KM et al. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J. 2010 Aug;31 (16):1975–84.
  39. Shanahan CM, Proudfoot D, Tyson KL, Cary NR, Edmonds M, Weissberg PL. Expression of mineralisation-regulating proteins in association with human vascular calcification. Z Kardiol. 2000;89 (Suppl 2):63–8.
  40. Braam LA, Dissel P, Gijsbers BL, Spronk HM, Hamulyak K, Soute BA et al. Assay for human matrix gla protein in serum: potential application in the cardiovascular field. Arterioscler Thromb Vasc Biol. 2000 May;20 (5):1257–61.
  41. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix gla protein. Nature. 1997 Mar 6;386 (6620):78–81.
  42. Donate-Correa J, Martin-Nunez E, Mora-Fernandez C, Muros-de-Fuentes M, Perez-Delgado N, Navarro-Gonzalez JF. Klotho in cardiovascular disease: Current and future perspectives. World J Biol Chem. 2015 Nov 26;6 (4):351–7.
  43. Hu MC, Kuro-o M, Moe OW. The emerging role of Klotho in clinical nephrology. Nephrol Dial Transplant. 2012 Jul;27 (7):2650–7.
  44. Hu MC, Kuro-o M, Moe OW. Klotho and kidney disease. J Nephrol. 2010 Nov-Dec;23 (Suppl 16):S136–44.
  45. Atkinson J. Age-related medial elastocalcinosis in arteries: mechanisms, animal models, and physiological consequences. J Appl Physiol (1985). 2008 Nov;105 (5):1643–51.
  46. Safar ME, O’Rourke MF. Volume 23. Arterial stiffness in hypertension. – Elsevier, 2006. – P.379–97.
  47. Беневоленская Л. И. Руководство по остеопорозу. – М.: Бином, 2003. – 524c [Benevolenskaya L. I. Rukovodstvo po osteoporozu. – M.: Binom, 2003. – 524c].
  48. von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999 Mar;106 (3):273–8.
  49. Christian RC, Harrington S, Edwards WD, Oberg AL, Fitzpatrick LA. Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women. J Clin Endocrinol Metab. 2002 Mar;87 (3):1062–7.
  50. Weitzmann MN, Pacifici R. Role of the immune system in postmenopausal bone loss. Curr Osteoporos Rep. 2005 Sep;3 (3):92–7.
  51. Чазов Е. И., Кухарчук В. В., Бойцов С. А. Руководство по атеросклерозу и ишемической болезни сердца. – М.: Медиа Медика, 2007. – 735c [Chazov E. I., Kuxarchuk V. V., Bojczov S. A. Rukovodstvo po aterosklerozu i ishemicheskoj bolezni serdcza. – M.: Media Medika, 2007. – 735c].
  52. Lee SH, Kim TS, Choi Y, Lorenzo J. Osteoimmunology: cytokines and the skeletal system. BMB Rep. 2008 Jul 31;41 (7):495–510.
  53. Pahmani F, Garfinkel A, Demer LL. Role of lipids in osteoporosis. Arterioscler Thromb Vasc Biol. 2000 Nov;20 (11):2346–48.
  54. Sprini D, Rini GB, Di Stefano L, Cianferotti L, Napoli N. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2014 May;11 (2):117–9.
  55. Tintut Y, Demer LL. Effects of bioactive lipids and lipoproteins on bone. Trends Endocrinol Metab. 2014 Feb;25 (2):53–9.
  56. Safar ME, Frohlich ED. Atherosclerosis, Large arteries and cardiovascular risk. Adv Cardiol. Basel, Karger 2007, vol.44, pp. 261–277.
  57. Орлова Я. А., Кузьмина А. Е., Баринова И. В. и др. Оценка жесткости магистральных артерий – новые перспективы неинвазивной диагностики коронарного атеросклероза. Терапевти­ческий архив. 2009;81 (4):8–13 [Orlova Ya. A., Kuz`mina A. E., Barinova I. V. i dr. Oczenka zhestkosti magistral`ny`x arterij – novy`e perspektivy` neinvazivnoj diagnostiki koronarnogo ateroskleroza. Terapevticheskij arxiv. 2009;81 (4):8–13].
  58. Safar M. E., London G. M. The arterial system in human hypertension. In Textbook of Hypertension, (ed. J. D. Swales), Blackwell Scientific, London, – 1994, – Р. 85–102 [Safar M. E., London G. M. The arterial system in human hypertension. In Textbook of Hypertension, (ed. J. D. Swales), Blackwell Scientific, London, – 1994, – R. 85–102]
  59. Dao HH, Essalihi R, Bouvet C, Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res. 2005 May 1;66 (2):307–17.
  60. Cecelja M, Jiang B, Bevan L, Frost ML, Spector TD, Chowienczyk PJ. Arterial stiffening relates to arterial calcification but not to noncalcified atheroma in women. A twin study. J Am Coll Cardiol. 2011 Mar 29;57 (13):1480–6.
  61. Widler L, Jahnke W, Green JR. The chemistry of bisphosphonates: from antiscaling agents to clinical therapeutics. Anticancer Agents Med Chem. 2012 Feb;12 (2):95–101.
  62. Santos LL, Cavalcanti TB, Bandeira FA. Vascular effects of bisphosphonates-a systematic review. Clin Med Insights Endocrinol Diabetes. 2012;5:47–54.
  63. Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M. Bisphos­phonates and atherosclerosis: why? Lupus. 2005;14 (9):773–9.
  64. Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphos­phonates. Joint Bone Spine. 2007 Jan;74 (1):32–8.
  65. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res. 2000 Mar;15 (3):599–604.
  66. Montagnani A, Gonnelli S, Cepollaro C, Campagna MS, Franci MB, Pacini S, Gennari C. Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate. Bone. 2003 Jan;32 (1):15–9.
  67. Bukowski JF, Dascher CC, Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun. 2005 Mar 18;328 (3):746–50.
  68. Rizzoli R, Reginster JY, Boonen S, Breart G, Diez-Perez A, Felsenberg D et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011 Aug;89 (2):91–104.
  69. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005 Dec;20 (12):2105–15.
  70. Ylitalo R, Monkkonen J, Urtti A, Ylitalo P. Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J Lab Clin Med. 1996 Feb;127 (2):200–6.
  71. Ylitalo R, Kalliovalkama J, Wu X, Kankaanranta H, Salenius JP, Sisto T et al. Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol.1998 Sep;83 (3):125–31.
  72. Rosenblum IY, Flora L, Eisenstein R. The effect of disodiumethane-1‑hydroxy-1,1‑diphosphonate (EHDP) on a rabbit model of athero-arteriosclerosis. Atherosclerosis. 1975 Nov-Dec;22 (3):411–24.
  73. Peller PJ, Ho VB, Kransdorf MJ. Extraosseous Tc-99m MDP uptake: a pathophysiologic approach. Radiographics. 1993 Jul;13 (4):715–34.
  74. Myers DT, Karvelis KC. Incidental detection of calcified dialysis graft onTc-99m MDP bone scan. Clin Nucl Med. 1998 Mar;23 (3):173–4.
  75. Ylitalo R. Bisphosphonates and atherosclerosis. Gen Pharmacol. 2000 Dec;35 (6):287–96.
  76. Wu L, Zhu L, Shi WH, Zhang J, Ma D, Yu B. Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur J Pharmacol. 2009 Jan 5;602 (1):124–31.
  77. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001 May;21 (5):817–24.
  78. Hill JA, Goldin JG, Gjertson D, Emerick AM, Greaser LD, Yoon HC et al. Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Acad Radiol. 2002 Oct;9 (10):1148–52.
  79. Tanko LB, Qin G, Alexandersen P, Bagger YZ, Christiansen C. Effective doses of ibandronate do not influence the 3‑year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int. 2005 Feb;16 (2):184–90.
  80. Toussaint ND, Lau KK, Strauss BJ, Polkighorne KR, Kerr PG. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis. 2010 Jul;56 (1):57–68.
  81. Kanazawa I, Yamaguchi T, Hayashi K, Takase H, Shimizu T, Sugimoto T. Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. Am J Med Sci. 2010 Jun;339 (6):519–24.
  82. Okamoto M, Yamanaka S, Yoshimoto W, Shigematsu T. Alendronate as an effective treatment for bone lossand vascular calcification in kidney transplant recipients. J Transplant. 2014;2014:269613.
  83. Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T. Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig. 2006;26 (4):215–22.
  84. Kawahara T, Nishikawa M, Furusawa T, Inazu T, Suzuki G. Effect of atorvastatin and etidronate combination therapy on regression of aortic atherosclerotic plaques evaluated by magnetic resonance imaging. J Atheroscler Thromb. 2011;18 (5):384–95.
  85. Kang JH, Keller JJ, Lin HC. Bisphosphonates reduced the risk of acute myocardial infarction: a 2‑year follow-up study. Osteoporos Int. 2013 Jan;24 (1):271–7.
  86. Kang JH, Keller JJ, Lin HC. A population-based 2‑year follow-up study on the relationship between bisphosphonates and the risk of stroke. Osteoporos Int. 2012 Oct;23 (10):2551–7.
  87. Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res. 2010 Jan;25 (1):91–7.
  88. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med. 2007;357: nihpa40967.
  89. Lu PY, Hsieh CF, Tsai YW, Huang WF. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin Ther. 2011 Sep;33 (9):1173–9.
  90. Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One. 2015 Apr 17;10 (4):e 0122646.
  91. Huang BT, Huang FY, Gui YY, Peng Y, Liu W, Huang KS et al. Association between bisphosphonates therapy and incident myocardial infarction: meta-analysis and trial sequential analysis. J Cardiovasc Pharmacol. 2015 Nov;66 (5):468–77.
Aslanyan N. S., Blankova Z. N., Vitsenya M. V., Mikhaylov G. V., Kulev B. D., Ageev F. T. Interrelationship of arterial calcinosis and osteoporosis. The effect of bisphosphonate therapy on the vascular wall. Russian Heart Journal. 2016;15 (3):151–160

To access this material please log in or register

Register Authorize
Ru En